Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors

被引:27
作者
Hilgeroth, A
Billich, A
Lilie, H
机构
[1] Univ Halle Wittenberg, Dept Pharm, D-06120 Halle, Germany
[2] Novartis Forsch Inst GMBH, Dept Antiretroviral Therapy, A-1235 Vienna, Austria
[3] Univ Halle Wittenberg, Dept Biochem & Biotechnol, D-06120 Halle, Germany
关键词
syn dimeric 4-aryl-1,4-dihydropyridines; HIV-1 protease inhibitor; competitive inhibition;
D O I
10.1016/S0223-5234(01)01228-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A first series of novel N-alkyl substituted syn dimeric 4-aryl-1,4-dihydropyridines 12-17 have been synthesised and evaluated as HIV-I protease inhibitors in in vitro assays. While the N-methyl derivatives 12 and 13 were almost inactive, with IC50-values of about 225 muM, the N-benzyl compounds with varied ester groups all exhibited stronger activities, with IC50-values of 11-12 muM for the presently best compounds 16 and 17 with ethyl ester functions. The type of HIV-1 protease inhibition of the novel inhibitors was characterised as competitive. With the increase of observed activity from N-methyl derivatives to N-benzyl compounds the binding mode may correspond to that of cyclic ureas with hydrophobic interactions of the four aromatic residues to the S1/S1' and S2/S2' regions of HIV-I protease. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 19 条
[1]  
Aristoff Paul A., 1998, Drugs of the Future, V23, P995, DOI 10.1358/dof.1998.023.09.858365
[2]  
CHENNAT T, 1975, J CHEM SOC P1, V10, P926, DOI DOI 10.1039/P19750000926
[3]  
De Lucca George V., 1998, Drugs of the Future, V23, P987, DOI 10.1358/dof.1998.023.09.473829
[4]  
Hilgeroth A, 1999, ARCH PHARM, V332, P380, DOI 10.1002/(SICI)1521-4184(199911)332:11<380::AID-ARDP380>3.0.CO
[5]  
2-T
[6]  
Hilgeroth A, 2000, PHARMAZIE, V55, P542
[7]  
Hilgeroth A, 2000, ARCH PHARM, V333, P195, DOI 10.1002/1521-4184(20006)333:6<195::AID-ARDP195>3.0.CO
[8]  
2-4
[9]  
Hilgeroth A, 1998, Pharm Unserer Zeit, V27, P22, DOI 10.1002/pauz.19980270107
[10]  
Hilgeroth A, 1998, Pharm Unserer Zeit, V27, P111, DOI 10.1002/pauz.19980270306